Last reviewed · How we verify

NCT05564884

Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

Status unknown Last updated 4 October 2022
What this trial tests

trial testing no intervantion in COVID-19 in 58 participants. Status unknown.

Timeline
12 September 2021
Primary endpoint
24 February 2022
1 November 2022

Quick facts

Lead sponsorRabin Medical Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment58
Start date12 September 2021
Primary completion24 February 2022
Estimated completion1 November 2022
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Rabin Medical Center

Who can join

Eligibility, female only, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Rabin Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05564884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing